Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 August 2023 | Story Andre Damons | Photo Andre Damons
Dr Kgomotso Moroka
Dr Kgomotso Moroka, Acting HOD: Cardiology in the UFS Faculty of Health Sciences, recently graduated from Maastricht University with a Diploma of Advanced Studies in Cardiac Arrhythmia Management (DAS-CAM).

A staff member from the University of the Free State (UFS) is hopeful her newly acquired skills and knowledge, following her graduation with a Diploma of Advanced Studies in Cardiac Arrhythmia Management (DAS-CAM) and completion of a electrophysiology fellowship, will contribute to the improvement of cardiovascular services in the Free State and Sub-Saharan Africa.

Dr Kgomotso Moroka, the Acting Head of Department (HOD) for Cardiology in the UFS Faculty of Health Sciences, recently graduated with a DAS-CAM in June 2023. This distinctive postgraduate programme is offered by Maastricht University in collaboration with the European Heart Rhythm Association and the European Society of Cardiology. This is a two-year programme and Dr Moroka was part of the third cohort which comprised 32 electrophysiologists selected from over 20 countries worldwide.

Her achievement places her as the sole   DAS-CAM graduate in Sub-Saharan Africa and the Free State region. 
Electrophysiology, which studies the electrical influences and patterns of the heart is vital for treating patients with abnormal heartbeats caused by irregularities in the heart’s electrical pathway, resulting in either unusually slow or fast heartbeats.

Seizing a valuable opportunity

Dr Moroka emphasises that currently, there is a lack of electrophysiology services provided in both the public and private sectors within the Free State. She therefore anticipates that her newly acquired skills and knowledge will play a pivotal role in enhancing and improving the cardiovascular services offered in the province. She is also optimistic about contributing to the establishment of a department dedicated to Electrophysiology Training. 

“I could not pass up the opportunity to engage with, learn and gain insights from seasoned world-class great minds of electrophysiology, who write the books we read and the very guidelines that we utilize in our daily practices. There was also an opportunity to be guided in research and the state-of-the-art cardiac clinical electrophysiology while also obtaining insights into how to develop a cardiac arrhythmia centre, biostatics, health economics, leadership skills and health technology assessment,” Dr Moroka explains regarding her motivation to enrol in the program. 

“It was a challenging and exciting program that allowed participants to engage with the world-renowned experts in electrophysiology not only on a professional but also personal level. This program served not only to educate participants on clinical cardiac electrophysiology but served to empower us to fulfil roles as future leaders in electrophysiology and in our day-to-day roles,” she continued.

Addressing the diverse burden of cardiac diseases

Dr Moroka believes that this qualification will significantly contribute to local efforts to establish and develop a much-needed unique service, thereby advancing her career development locally and on the international platform. This qualification enables her to expand her clinical research pursuits on multiple fronts.

Dr Moroka underscores the substantial burden of ischemic heart disease with the associated risk factors such as uncontrolled high blood pressure, diabetes, elevated cholesterol levels and smoking. “There is a measurable burden of heart failure and valvular heart disease. In addition, from the research that we hope to embark upon, we hope to clearly define the burden of rhythm problems such as atrial fibrillation and other arrhythmias which are serious conditions. With the available skills and knowledge, we can begin to offer alternative adjunctive treatment that would have a significant positive effect on the morbidity and/or mortality of our patients.”

Dr Moroka points out that with the advent and advances in machine learning and digital health technology, we are in an exciting era of possibilities of obtaining valuable biological data and biometric parameters that would assist in the reduction of risk and prevention of a diversity of cardiovascular diseases and to guide clinical practice guidelines. 

“The current focus is risk reduction, prevention of cardiovascular diseases and the establishment and development of personalized health care, with a growing interest in cardiovascular genetics and gene therapy.  Who knows what the future will bring, but for now the focus is to work towards good health and disease alleviation,” she says. 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept